<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102518/results/search/test_trace/results.xml">
  <result pre="advance to complicated disease and reduce case-fatality rates. Standard-of-care is" exact="treatment" post="with neuraminidase inhibitors that prevent viral dissemination. In 2018,"/>
  <result pre="2018, the first mechanistically new influenza drug class for the" exact="treatment" post="of uncomplicated seasonal influenza in 2 decades was approved"/>
  <result pre="up to 650,000 deaths annually.1 High-risk groups for severe influenza" exact="infection" post="include older adults, the immunocompromized, pregnant women, people with"/>
  <result pre="WINDOW FOR TARGETING OF INFLUENZA VIRUS REPLICATION Whereas influenza virus" exact="infection" post="causes direct cell damage in the airway epithelium, severe"/>
  <result pre="largely a consequence of immunopathogenesis and peaks after the acute" exact="infection" post="has been cleared. Influenza virus load in the upper"/>
  <result pre="replication outline a narrow therapeutic window for influenza drugs. Ideally," exact="treatment" post="should be initiated within 24–36 hours of infection. In"/>
  <result pre="inhibitors (NAIs) have revealed a benefit for the patient when" exact="treatment" post="was initiated within 48 hours of the onset of"/>
  <result pre="and, subsequently, rimantadine, were the first drugs approved for the" exact="treatment" post="of influenza A virus (IAV) infections. These inhibitors target"/>
  <result pre="and H1N1 strains carried resistance mutations to amantadine.14 This high" exact="prevalence" post="of resistance to the adamantanes is thought to directly"/>
  <result pre="B virus; RdRP, RNA-dependent RNA polymerase. ⁎not recommended for antiviral" exact="treatment" post="against currently circulating influenza virus strains due to high"/>
  <result pre="hospitalization,34, 35, 36, 37 and some data suggested that late" exact="treatment" post="with NAIs could have enhanced the risk of progression"/>
  <result pre="is relatively rare in currently endemic influenza virus strains,42,43 the" exact="prevalence" post="of escape mutations increased rapidly in the 2007/2008 influenza"/>
  <result pre="new influenza drug class approved in 2 decades for the" exact="treatment" post="of uncomplicated influenza infection in patients older than 12"/>
  <result pre="approved in 2 decades for the treatment of uncomplicated influenza" exact="infection" post="in patients older than 12 years of age.70 Taken"/>
  <result pre="showed significantly lower viral burden 1 day after initiation of" exact="treatment" post="compared to placebo groups, and the time to alleviation"/>
  <result pre="can be achieved with NAIs.72 Quite remarkably, twice daily experimental" exact="treatment" post="of mice infected with a lethal dose of a"/>
  <result pre="animal body weight and lung viral loads were identical after" exact="infection" post="with resistant or sensitive viruses, and substitutions at PA"/>
  <result pre="is referred to the Web version of this article.) Safety" exact="testing" post="revealed that T-705 is teratogenic and embryotoxic at concentrations"/>
  <result pre="approved human dose.99,102 Although conditionally licensed in Japan for the" exact="treatment" post="of pathogenic influenza viruses resistant to other therapeutics, these"/>
  <result pre="lung tissue was unchanged from that in controls after extended" exact="treatment" post="of animals with 200 mg/kg daily dose and thus"/>
  <result pre="polymerase PB2 subunit. The drug outperformed current standard-of-care in animal" exact="infection" post="models of H3N2 and H1N1 viruses, although potency was"/>
  <result pre="bnAbs are attractive for the protection of high-risk groups if" exact="treatment" post="costs can be managed. Competitive ribonucleoside analog inhibitors with"/>
  <result pre="and influenza vaccine-induced immunityCell Immunol2019103998 6BaccamP.BeaucheminC.MackenC.A.HaydenF.G.PerelsonA.S.Kinetics of influenza A virus" exact="infection" post="in humansJ Virol8020067590759916840338 7DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for influenza in adults:"/>
  <result pre="6BaccamP.BeaucheminC.MackenC.A.HaydenF.G.PerelsonA.S.Kinetics of influenza A virus infection in humansJ Virol8020067590759916840338 7DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir" exact="treatment" post="for influenza in adults: a meta-analysis of randomised controlled"/>
  <result pre="Oral Neuraminidase Study GroupJAMA.28320001016102410697061 11NicholsonK.G.AokiF.Y.OsterhausA.D.Efficacy and safety of oseltamivir in" exact="treatment" post="of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor"/>
  <result pre="trial. Neuraminidase Inhibitor Flu Treatment Investigator GroupLancet.35520001845185010866439 12VemulaS.V.ZhaoJ.LiuJ.WangX.BiswasS.HewlettI.Current approaches for" exact="diagnosis" post="of influenza virus infections in humansViruses820169627077877 13JacksonR.J.CooperK.L.TappendenP.Oseltamivir, zanamivir and"/>
  <result pre="phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the" exact="treatment" post="of respiratory syncytial virus upper respiratory tract infection in"/>
  <result pre="for the treatment of respiratory syncytial virus upper respiratory tract" exact="infection" post="in hematopoietic-cell transplant recipientsClin Infect Dis2019[epub ahead of print]"/>
  <result pre="A (H1N1) viruses harboring amantadine resistance mutationsAntimicrob Agents Chemother49200555655915673732 23KrumbholzA.SchmidtkeM.BergmannS.High" exact="prevalence" post="of amantadine resistance among circulating European porcine influenza A"/>
  <result pre="Other Resp Viruses720132536 33ObohoI.K.ReedC.GargiulloP.Benefit of early initiation of influenza antiviral" exact="treatment" post="to pregnant women hospitalized with laboratory-confirmed influenzaJ Infect Dis214201650751526908745"/>
  <result pre="hospitalized with laboratory-confirmed influenzaJ Infect Dis214201650751526908745 34MuthuriS.G.MylesP.R.VenkatesanS.Leonardi-BeeJ.Nguyen-Van-TamJ.S.Impact of neuraminidase inhibitor" exact="treatment" post="on outcomes of public health importance during the 2009-2010"/>
  <result pre="38MichielsB.Van PuyenbroeckK.VerhoevenV.VermeireE.CoenenS.The value of neuraminidase inhibitors for the prevention and" exact="treatment" post="of seasonal influenza: a systematic review of systematic reviewsPLoS"/>
  <result pre="novel approaches in influenza managementVaccines (Basel)7201953 65LaursenN.S.FriesenR.H.E.ZhuX.Universal protection against influenza" exact="infection" post="by a multidomain antibody to influenza hemagglutininScience362201859860230385580 66OrtinJ.Martin-BenitoJ.The RNA"/>
  <result pre="9, e00a30-18, 2018)Mbio.92018e00430-1829691337 82OmotoS.SperanziniV.HashimotoT.Characterization of influenza virus variants induced by" exact="treatment" post="with the endonuclease inhibitor baloxavir marboxilSci Rep82018963329941893 83ImaiM.YamashitaM.Sakai-TagawaY.Influenza A"/>
  <result pre="in vitro norovirus replicationBiochem Bioph Res Co4242012777780 92JulanderJ.G.SmeeD.F.MorreyJ.D.FurutaY.Effect of T-705" exact="treatment" post="on western equine encephalitis in a mouse modelAntiviral Res82200916917119428608"/>
  <result pre="orally administered T-705 pyrazine analog on lethal West Nile virus" exact="infection" post="in rodentsAntiviral Res80200837737918762216 94GowenB.B.WongM.H.JungK.H.In vitro and in vivo activities"/>
  <result pre="pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for" exact="treatment" post="of acute uncomplicated seasonal influenza A: TOPAZ trialJ Infect"/>
 </snippets>
</snippetsTree>
